27 unknown, 16 recruiting, 7 not yet recruiting, 7 withdrawn. 48 Phase 2, 15 Phase 3, 6 Phase 1, 2 Not applicable, 1 Phase 4.
Follow PD-1 Antibody: new trials by email Literature Review of PD-1 Antibody trials Research Report on PD-1 Antibody
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study Sintilimab, ipilimumab, Radscopal Radiotherapy - Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-09-01 | 2026-08-10 |
| Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM SBRT, PD-1 Antibody, H101 - CRC, Liver Metastasis Colon Cancer | Phase 2 | Not yet recruiting | Jun Huang | 114 | 2026-06-01 | 2026-04-28 |
| Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC Vebrekotuzumab, PD-1 antibody - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Fudan University | 104 | 2026-04-30 | 2026-07-07 |
| PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL PD-1 antibody, radiotherapy, Chidamide - Natural Killer/T-cell Lymphoma | Phase 2 | Recruiting | Ruijin Hospital | 47 | 2026-03-01 | 2026-03-20 |
| NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC PD-1 antibody, NK010 - Resectable Non-small Cell Lung Cancer | Phase 1 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 10 | 2026-01-20 | 2026-01-06 |
| PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer Serplulimab, FOLFOXIRI chemotherapy, CAPOX chemotherapy - Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer) | Phase 3 | Not yet recruiting | Sun Yat-sen University | 382 | 2025-12-29 | 2025-12-11 |
| EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin - Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 148 | 2025-07-09 | 2026-05-11 |
| PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer PD-1 antibody, PD-L1 antibody, Chemotherapy and bevacizumab (CT-BEV) - Metastatic Cervical Cancer, Persistent Cervical Cancer | Phase 2 / Phase 3 | Recruiting | N.N. Alexandrov National Cancer Centre | 120 | 2025-07-01 | 2026-05-28 |
| PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma Sintilimab, Capecitabine - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Not yet recruiting | Sun Yat-sen University | 664 | 2025-05-01 | 2025-04-02 |
| Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer Conventional Radiotherapy, Capecitabine, 5-fluorouracil - Locally Recurrent Rectal Cancer | Phase 2 | Recruiting | Fudan University | 221 | 2025-03-10 | 2025-04-15 |
| CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC Ultrafractionated RT and CGA Guided systemic treatment., Ultrafractionated Radiotherapy, PD-1 antibody - Colon Cancer, Rectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 110 | 2024-11-01 | 2024-10-30 |
| Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT) Toripalimab, Cetuximab, Albumin-Bound Paclitaxel - Squamous Cell Carcinoma of Head and Neck | Phase 3 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 355 | 2024-11-01 | 2024-10-18 |
| MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer PD-1 antibody, Oxaliplatin, Capecitabine - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Fudan University | 46 | 2024-08-13 | 2025-02-21 |
| Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer node-sparing modified short-course radiotherapy, PD-1 antibody, Capecitabine - Rectal Cancer | Phase 3 | Active not recruiting | Sir Run Run Shaw Hospital | 170 | 2024-07-29 | 2026-06-30 |
| Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) Radiation, PD-1 antibody, Capecitabine - Rectal Cancer | Phase 2 | Recruiting | Fudan University | 60 | 2024-05-08 | 2024-06-13 |
| PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC Sapropterin Dihydrochloride - Pancreatic Adenocarcinoma Metastatic | Phase 2 | Unknown | Sun Yat-sen University | 20 | 2024-04-30 | 2024-05-02 |
| Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma PD-1inhibitor, Fruquintinib, albumin paclitaxel - Gastric Cancer | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2024-04-15 | 2026-07-28 | |
| Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer Tislelizumab, Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), Carboplatin or Cisplatin - Non-small-cell Lung Cancer (NSCLC) | Phase 4 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2024-01-18 | 2024-04-10 |
| Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence SBRT, Chemotherapy, PD-1 antibody - Radiotherapy, Immunotherapy | Phase 2 | Unknown | Fudan University | 80 | 2023-09-25 | 2023-11-07 |
| Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer Modified short-course radiotherapy, PD-1 antibody, Capecitabine - Low Rectal Cancer | Phase 2 | Recruiting | Sir Run Run Shaw Hospital | 32 | 2023-08-02 | 2025-01-09 |
Showing 20 of 66. Sign in to see all of them.
Carcinoma, Hepatocellular (8) · Nasopharyngeal Carcinoma (8) · Carcinoma, Non-Small-Cell Lung (5) · Stomach Neoplasms (5) · Rectal Neoplasms (4) · Nasopharyngeal Neoplasms (3) · Recurrence (3) · Uterine Cervical Neoplasms (3) · Colorectal Neoplasms (2) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Digestive System Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1)
Sun Yat-sen University (20) · Fudan University (12) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Peking University Third Hospital (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Shi Ming (2) · Sir Run Run Shaw Hospital (2) · Cancer Hospital of Guangxi Medical University (1) · China Medical University, China (1) · Eye & ENT Hospital of Fudan University (1) · First Affiliated Hospital of Guangxi Medical University (1) · Fujian Cancer Hospital (1) · Henan Cancer Hospital (1) · HitGen Inc. (1) · Huiqiang Huang (1)
China (62) · Belarus (1)
Ming Shi, MD (6) · Jun Ma, MD (2) · Zhen Zhang, M.D, PH.D (2) · Baorui Baorui Liu, Doctor (1) · Baoshan Cao (1) · Bin Zhang, M.D. (1) · Chang Chen, MD, PhD (1) · Fan Xia, M.D,PH.D (1) · Huiqiang Huang, Professor (1) · Jian Zhang, M.D. (1) · Jiazhou Ye, M.D. (1) · Jingao Li, M.D. (1) · Jingdong Zhang (1) · Jun Chen (1) · Jun Huang (1)
PMID 26028255, PMID 28241187, PMID 29727332, PMID 31513484, PMID 32251400, PMID 35291966, PMID 35355438, PMID 37032401, PMID 37056765, PMID 37802608, PMID 38053659, PMID 38167937, PMID 38353107, PMID 38763304, PMID 38824941, PMID 38950321, PMID 39385104, PMID 39438442, PMID 40413023, PMID 40651471, PMID 40652024, PMID 41087995, PMID 41791006, PMID 42252705